中华老年心脑血管病杂志

[1] Villemagne VL,Fodero-Tavoletti MT,Masters CL,et al.Tau imaging:early progress and future directions[J].Lancet Neurol,2015,14(1):114-124. DOI:10.1016/S1474-4422(14)70252-2.

[2]王小琪,韩璎.阿尔茨海默病诊断标准的演变[J].医学研究杂志,2018,47(7):169-172.DOI:10.11969/j.issn.1673-548X.2018.07.039.

[3] Harada R,Okamura N,Furumoto S,et al.18 F-THK5351:a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease[J].J Nucl Med,2016,57(2):208-214.DOI:10.2967/jnumed.115.164848.

[4] Lowe VJ,Curran G,Fang P,et al.An autoradiographic evaluation of AV-1451tau PET in dementia[J].Acta Neuropathol Commun,2016,4(1):58. DOI:10.1186/s40478-016-0315-6.

[5] Ono M,Sahara N,Kumata K,et al.Distinct binding of PET ligands PBB3and AV-1451to tau fibril strains in neurodegenerative tauopathies[J].Brain,2017,140(3):764-780.DOI:10.1093/brain/aww339.

[6] Harada R,Okamura N,Furumoto S,et al.18 F THK-5117PET for assessing neurofibrillary pathology in Alzheimer's disease[J].Eur J Nucl Med Mol Imaging,2015,42(7):1052-1061. DOI:10.1007/s00259-015-3035-4.

[7] Lockhart SN,Baker SL,Okamura N,et al.Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer's disease patients measured using18F THK-5351[J].PLoS One,2016,11(6):e0158460.DOI:10.1371/journal.pone.0158460.

[8] Chiotis K,Saint-Aubert L,Savitcheva I,et al.Imaging in-vivo tau pathology in Alzheimer's disease with THK5317PET in a multimodal paradigm[J].Eur J Nucl Med Mol Imaging,2016,43(9):1686-1699. DOI:10.1007/s00259-016-3363-z.

[9] Sch9ll M,Lockhart SN,Schonhaut DR,et al.PET imaging of tau deposition in the aging human brain[J].Neuron,2016,89(5):971-982. DOI:10.1016/j.neuron.2016.01.028.

[10] Cho H,Choi JY,Hwang MS,et al.In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum[J].Ann Neurol,2016,80(2):247-258. DOI:10.1002/ana.24711.

[11] Ossenkoppele R,Schonhaut DR,Sch9ll M,et al.Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease[J].Brain,2016,139(Pt5):1551-1567.DOI:10.1093/brain/aww027.

[12] MarquiéM,Normandin MD,Vanderburg CR,et al.Validating novel tau positron emission tomography tracer 18F‐AV1451(T807)on postmortem brain tissue[J].Ann Neurol,2015,78(5):787-800. DOI:10.1002/ana.24517.

[13] Dubois B,Hampel H,Feldman HH,et al.Preclinical Alzheimer's disease:definition,natural history,and diagnostic criteria[J].Alzheimers Dement,2016,12(3):292-323.DOI:10.1016/j.jalz.2016.02.002.

[14] Johnson KA,Schultz A,Betensky RA,et al.Tau positron emission tomographic imaging in aging and early Alzheimer disease[J].Ann Neurol,2016,79(1):110-119. DOI:10.1002/ana.24546.

[15] Pontecorvo MJ,Devous MD Sr,Navitsky M,et al.Relationships between flortaucipir PET tau binding and amyloid burden,clinical diagnosis,age and cognition[J].Brain,2017,140(3):748-763. DOI:10.1093/brain/aww334.

[16] Cho H,Choi JY,Hwang MS,et al.Tau PET in Alzheimer disease and mild cognitive impairment[J].Neurology,2016,87(4):375-383. DOI:10.1212/WNL.0000000000002892.

[17] Smith R,Schain M,Nilsson C,et al.Increased basal ganglia binding of 18F-AV-1451in patients with progressive supranuclear palsy[J].Mov Disord,2017,32(1):108-114. DOI:10.1002/mds.26813.

[18] Cho H,Choi JY,Hwang MS,et al.Subcortical 18F-AV-1451binding patterns in progressive supranuclear palsy[J].Mov Disord,2017,32(1):134-140. DOI:10.1002/mds.26844.

[19] Whitwell JL,Lowe VJ,Tosakulwong N,et al.[18F]AV-1451tau positron emission tomography in progressive supranuclear palsy[J].Mov Disord,2017,32(1):124-133.DOI:10.1002/mds.26834.

[20] Kepe V,Bordelon Y,Boxer A,et al.PET imaging of neuropathology in tauopathies:progressive supranuclear palsy[J].J Alzheimers Dis,2013,36(1):145-153. DOI:10.3233/JAD-130032.

[21] Gomperts SN,Marquie M,Locascio JJ,et al.PET radioligands reveal the basis of dementia in Parkinson's disease and dementia with Lewy bodies[J].Neurodegener Dis,2016,16(1-2):118-124. DOI:10.1159/000441421.

[22] Kantarci K,Lowe VJ,Boeve BF,et al.AV-1451tau andβ-amyloid positron emission tomography imaging in dementia with Lewy bodies[J].Ann Neurol,2017,81(1):58-67. DOI:10.1002/ana.24825.

[23] DeKosky ST,Blennow K,Ikonomovic MD,et al.Acute and chronic traumatic encephalopathies:pathogenesis and biomarkers[J].Nat Rev Neurol,2013,9(4):192-200. DOI:10.1038/nrneurol.2013.36.

[24] Nelson PT,Alafuzoff I,Bigio EH,et al.Correlation of Alzheimer disease neuropathologic changes with cognitive status:a review of the literature[J].J Neuropathol Exp Neurol,2012,71(5):362-381. DOI:10.1097/NEN.0b013e31825018f7.